Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-13
2007-03-13
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S201000
Reexamination Certificate
active
10415693
ABSTRACT:
The invention relates to indolyl piperidinyl derivatives of formula (I) wherein: A1represents an alkylene, alkyleneoxy, alkylenethio, alkanoylene or hydroxyalkylene group; A2represents an alkylene, alkyleneoxy, alkylenethio, alkanoylene or an alkyleneoxyalkylene group; W1represents a phenylene, furanylene or pyridinylene group which is unsubstituted or substituted by one or more halogen atoms, alkoxy groups and/or alkyl groups; W2represents a 3–10 membered monocyclic or bicyclic group containing from 1 to 3 heteroatoms said group being unsubstituted or substituted by one or more halogen atoms, alkyl groups, alkoxy groups and/or oxo groups; R1represents a hydrogen or halogen atom or an alkyl, alkoxy or methylamino group; and R2represents a carboxyl group; and pharmaceutically acceptable salts thereof; to processes for their preparation; to pharmaceutical compositions containing them; and to their medical use as antihistaminic and antiallergic agents.
REFERENCES:
patent: 4602016 (1986-07-01), Cross et al.
patent: 4843068 (1989-06-01), Hamaguchi et al.
patent: 5650416 (1997-07-01), Carr et al.
patent: 5670511 (1997-09-01), Marz et al.
patent: 6462056 (2002-10-01), Böttcher et al.
patent: 0 224 919 (1986-06-01), None
patent: 0 324 431 (1989-07-01), None
patent: 0 648 759 (1995-04-01), None
patent: 0 722 942 (1996-07-01), None
patent: WO 95/01350 (1995-01-01), None
patent: WO 98/38189 (1998-09-01), None
patent: WO 99/17773 (1999-04-01), None
patent: WO 00/75130 (2000-12-01), None
patent: WO 01/96328 (2001-12-01), None
Pesenti et al. “Influence of fluorinated molecules . . . ” ChemBioChem. v.5, p. 591-613 (2004).
Wermuth “The practice of medicinal chemistry” Acad. Press, p. 203-206 (1996).
Seifert et al., Journal of Pharmacology and Experimental Therapeutics, 2003, pp. 1104-1115.
Garcia-Careaga et al., Nutr. Clin. Pract., 2005, 20(5), abstract.
Perregaard, J. et al., (1992) “Selective, Centrally Acting Serotonin 5-HT2Antagonists. 1. 2- and 6-Substituted 1-Phenyl-3-(4-piperidinyl)-1H-indoles,”J. Med. Chem. 35:4813-1822.
Shigenaga, S. et al., (1996) “(2E,4E)-N-(4-(1H-Indol-3-yl)poperidin-1-yl)alkyl-5-(substituted phenyl)-2,4-pentadienamides as Antiallergic Agents with Antihistaminic and Anti Slow-Reacting Substance (SRS) Activities,”Arch. Pharm. Pharm. Med. Chem. 329:3-10.
Chang, R. S. L. et al. (1979). “Heterogeneity of Histamine H1-Receptors: Species Variations in [3H]Mepyramine Binding of Brain Membranes”Journal of Neurochemistry32:1653-1663.
Leysen, J. E. et al. (1991), “Comparative Study of Central and Peripheral Histamine-H1Receptor Binding In Vitro and Ex Vivo of Non-Sedating Antihistamines and of Noberastine, a New Agent”Drug Development Research22:165-178.
Duran Carles Puig
Fonquerna Pou Silvia
Pages Santacana Lluis
Soca Pueyo Lidia
Almirall Prodesfarma S.A.
Chang Celia
Morrison & Foerster / LLP
LandOfFree
Indolylpiperidine derivatives as antihistaminic and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indolylpiperidine derivatives as antihistaminic and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indolylpiperidine derivatives as antihistaminic and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3802262